ICON Public Limited Company (ICLR) Stock: Price, Forecast & Analyst Target
ICON Public Limited Company (ICLR) — MoonshotScore 73/100 (Strong band), calculated Nov 18, 2026. Price $190.36 (-2.46%), as of the Nov 19, 2026 trading session; market cap $14.3B.
Educational signal · not a buy or sell recommendation · How to read this
ICON Public Limited Company · ICLR · NASDAQ · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered): ICON runs clinical development programs for drug, biotechnology, medical-device and public-health customers, combining study execution with laboratories, data, staffing and commercialization support. The share case rests on whether resilient demand can restore profit conversion while cash generation carries a debt-heavy capital structure.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · ICON Public Limited Company (ICLR)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $2.02B (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 4 of the last 8 reports
- Altman Z 2.14 · Piotroski F 7
Helping: business quality, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 72 | Strong | |
| 73 | Strong | |
| 72 | Strong | |
| 72 | Strong | |
| 73 | Strong | |
| 73 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $190.36 | |
| Change on the day | -2.46% | |
| 52-week range | $66.57–$219.04 | |
| Market capitalisation | $14.3B | — |
| Price / earnings (trailing) | 33.34 | |
| Shares traded on the day | 939.7K | |
| Beta (volatility vs the S&P 500) | 1.19 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for ICON Public Limited Company (ICLR): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is ICON Public Limited Company (ICLR), and what does it report?
Short answer · as of
ICON is a clinical research organization, not primarily a seller of diagnostic tests.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Customers outsource the design, management and analysis of clinical programs, along with laboratory work, patient and site access, staffing, data services and post-market support.
Reported revenue therefore measures a broad portfolio of development services delivered across regions and customer types. The consolidated results reflect the economics of that service platform: substantial revenue can coexist with much thinner net profit when delivery costs and operating expenses absorb more of the gross profit pool.
What do the latest results show for ICON Public Limited Company (ICLR)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $2.02B.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
The latest period brought sequential revenue growth and a result above the market estimate. Gross profit and net income nevertheless fell, while operating profit improved, leaving a split picture: demand held up better than profitability available to shareholders.
Management kept its annual revenue and adjusted earnings guidance unchanged. That stance is a management expectation rather than evidence that the recent gross-profit pressure has cleared, especially after annual revenue was broadly steady while annual net income contracted sharply.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $2.02B | $122M | $1.58 (diluted) |
| Q2 FY2026 | $2.06B | $73M | $0.94 (diluted) |
| Q1 FY2026 | $2.03B | $105M | $1.36 (diluted) |
| Q4 FY2025 | $2.11B | $149M | $1.93 (diluted) |
What are the financial strengths and risks for ICON Public Limited Company (ICLR)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
Operating cash flow has remained positive across the displayed periods, and recent cash accumulation has strengthened liquidity. Capital spending has consumed far less cash than operations produced in most periods, supporting healthy free-cash-flow conversion despite uneven reported earnings.
Debt still exceeds cash and investments by a wide margin, while near-term liquidity ratios sit close to full coverage rather than offering a deep cushion. ICON is therefore exposed less to immediate cash burn than to sustained profit compression or weaker cash conversion that would reduce room to manage leverage.
The business risk is tied directly to outsourced clinical activity: less study execution, laboratory work, staffing or post-market support would pressure utilization across a large service workforce. Because the platform spans many linked services, weaker customer program activity can reach revenue, margin and cash generation together.
What should you watch next at ICON Public Limited Company (ICLR)?
Short answer · as of
Current published price targets run low $105.00 · high $268.00 · consensus $217.50 · median $232.50 against a quoted price of $190.36 (as of Nov 19, 2026).
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
The next result should be judged through the relationship among revenue, gross profit and operating cash flow. Revenue holding near recent levels would matter less if gross profit continues to contract or cash conversion weakens.
Watch whether performance remains compatible with unchanged management guidance and with market estimates that assume renewed revenue and earnings growth over the forecast horizon. Continued cash accumulation would improve financial flexibility; debt reduction would provide a stronger confirmation that operating cash is reaching the balance sheet.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does ICON Public Limited Company compare with its peers?
Short answer
ICON Public Limited Company's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered).
ICON competes as a broad clinical-development partner rather than a narrow laboratory or staffing vendor. Its offering connects trial design and execution with data, imaging, language, laboratory, patient-access and commercialization services, while supporting full-service engagements and functional service partnerships.
That breadth makes delivery scale and workforce utilization central to the comparison with more specialized research providers. ICON’s attraction is the ability to serve more of a customer’s development program; the tradeoff is that weak profit conversion across a large platform can outweigh stable consolidated revenue.
| Company | Price | Market value | Score |
|---|---|---|---|
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $1705.66 Nov 19, 2026 | $33.9B | 93 5-pillar Nov 18, 2026 | |
| $633.98 Nov 19, 2026 | $17.7B | 92 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| $49.63 Nov 19, 2026 | $10.3B | 83 5-pillar Nov 18, 2026 | |
| $258.99 Nov 19, 2026 | $28.5B | 74 5-pillar Nov 18, 2026 | |
| ICON Public Limited Company (ICLR) — this page | $190.36 | $14.3B | 73 |
| $151.59 Nov 19, 2026 | $16.9B | 71 5-pillar Nov 18, 2026 | |
| $370.78 Nov 18, 2026 | $30.1B | 71 5-pillar Nov 18, 2026 | |
| $327.93 Nov 19, 2026 | $15.7B | 70 5-pillar Nov 18, 2026 | |
| $60.33 Nov 19, 2026 | $11.5B | 40 5-pillar Nov 18, 2026 | |
| $289.50 Nov 18, 2026 | $42.0B | 36 5-pillar Nov 18, 2026 | |
| $111.62 Nov 19, 2026 | $7.61B | 35 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $105.00 – $268.00
- Consensus target
- $217.50
- Median target
- $232.50
Consensus record · Captured .
Measured against a quoted price of $190.36 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 60
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 37
- Other transactions
- 23
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ICLR in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.10% | $22.84M | New position |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about ICON Public Limited Company (ICLR)?
ICLR Healthcare Stock FAQ
Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Does ICON’s laboratory offering make it a diagnostics company?
ICON uses laboratory services inside a wider outsourced clinical-development platform. Its work extends from program design and study execution through patient access, data analysis and post-market commercialization.
Why did ICON’s latest revenue beat not produce stronger profit?
Revenue exceeded the market estimate, but gross profit and net income declined from the preceding period. The result shows that customer activity and shareholder profit conversion did not move together.
How do ICON’s full-service partnerships turn study activity into cash?
Full-service and functional partnerships let ICON provide labor, laboratories, data and trial operations across customer programs. Recent positive operating cash flow shows that this service activity is converting into cash, although the amount has varied materially between periods.
What does ICON’s Advarra alliance add to its trial-site model?
The alliance is intended to develop a connected network of research-ready clinical trial sites. It complements ICON’s existing site and patient access services rather than changing the company into a site owner.
What is the ICLR stock price today?
The last price recorded for ICON Public Limited Company (ICLR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ICLR price target?
The analyst consensus price target for ICON Public Limited Company (ICLR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold ICLR
Funds in our ETF coverage that list ICLR among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares MSCI Ireland ETF (EIRL) | 4.96% |